What does Newton Biocapital II Partners do?

Newton Biocapital II Partners is filed with the CBE under the catch-all “Overige financiële dienstverlening”, a code that says little about what the company actually does. Private Limited, started on 4 May 2021, 1 establishment.

What is the address of Newton Biocapital II Partners?

The registered office of Newton Biocapital II Partners is located at Tervurenlaan 273, 1150 Sint-Pieters-Woluwe.

Is Newton Biocapital II Partners still active?

Yes. According to the CBE (17 September 2026) Newton Biocapital II Partners is active, legal situation “Normale toestand”, started on 4 May 2021.

Is Newton Biocapital II Partners registered on Peppol?

Yes, Newton Biocapital II Partners is registered on the Peppol network with ID 0208:0767828541.

What is the enterprise number of Newton Biocapital II Partners?

The enterprise number of Newton Biocapital II Partners is BE0767828541.

When was Newton Biocapital II Partners founded?

Newton Biocapital II Partners was founded on 4 May 2021.

Is Newton Biocapital II Partners a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 4 May 2021; 5 annual accounts filed, latest fiscal year 2025; 5 directors known from the annual account.

How much profit did Newton Biocapital II Partners make in 2025?

Newton Biocapital II Partners posted a profit after taxes of € 4,082 in financial year 2025.

What is the revenue of Newton Biocapital II Partners?

As a small company, Newton Biocapital II Partners is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 8,285.

Newton Biocapital II Partners (Private Limited)

Q: Who are the directors of Newton Biocapital II Partners?

According to the 2025 annual accounts, the directors of Newton Biocapital II Partners are: DANNY GONNISSEN SRL, HEYNEN CONSULTING AG S. Etr., ROAD MEDICAL GODOKAISHA S. Etr., A Q INVEST SRL, BIOSS S. Etr..

Dossier Newton Biocapital II Partners, printed on 17 September 2026 from databakkes.be/en/0767828541/newton-biocapital-ii-partners. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Negative equity NBB

More debt than assets in 4 of the last 4 fiscal years.
Busy address KBO

21 other companies have their registered office at the same address; threshold 10.

Financials

Financial year 2025

Newton Biocapital II Partners from Sint-Pieters-Woluwe, company number BE0767828541, closed financial year 2025 with a result of € 4,082 after tax. For that financial year Newton Biocapital II Partners recorded a gross margin of € 8,285 and equity of € -10,112. Compared with financial year 2024, the result moved from € 63,752 to € 4,082. The company is profitable. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 2, 2026.

What it is worth Caution

€ -10,112

▲ € 4,082 vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 4,082

▼ 94% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 44,927

▼ 35% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € -18,112.

People and assets in 2025

Vehicles and equipment

€ 2,074

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 57,435

▼ 27% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 1,869

▼ 73% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ -174,384 Gross margin 2022: € -174,384 First fiscal year in the series	€ 93,587 Gross margin 2023: € 93,587 ▲ € 267,970 vs 2022 (€ -174,384) Favourable step	€ 73,216 Gross margin 2024: € 73,216 ▼ 22% vs 2023 (€ 93,587) Unfavourable step	€ 8,285 Gross margin 2025: € 8,285 ▼ 89% vs 2024 (€ 73,216) Unfavourable step	▼ 89%
Profit after taxes	€ -175,540 Profit after taxes 2022: € -175,540 First fiscal year in the series	€ 91,371 Profit after taxes 2023: € 91,371 ▲ € 266,911 vs 2022 (€ -175,540) Favourable step	€ 63,752 Profit after taxes 2024: € 63,752 ▼ 30% vs 2023 (€ 91,371) Unfavourable step	€ 4,082 Profit after taxes 2025: € 4,082 ▼ 94% vs 2024 (€ 63,752) Unfavourable step	▼ 94%
Equity	€ -169,316 Equity 2022: € -169,316 First fiscal year in the series	€ -77,945 Equity 2023: € -77,945 ▲ € 91,371 vs 2022 (€ -169,316) Favourable step	€ -14,194 Equity 2024: € -14,194 ▲ € 63,752 vs 2023 (€ -77,945) Favourable step	€ -10,112 Equity 2025: € -10,112 ▲ € 4,082 vs 2024 (€ -14,194) Favourable step	▲ € 4,082
Total debts	€ 172,613 Total debts 2022: € 172,613 First fiscal year in the series	€ 146,128 Total debts 2023: € 146,128 ▼ 15% vs 2022 (€ 172,613) Favourable step	€ 85,090 Total debts 2024: € 85,090 ▼ 42% vs 2023 (€ 146,128) Favourable step	€ 59,336 Total debts 2025: € 59,336 ▼ 30% vs 2024 (€ 85,090) Favourable step	▼ 30%
Cash	€ 3,285 Cash 2022: € 3,285 First fiscal year in the series	€ 36,927 Cash 2023: € 36,927 ▲ € 33,642 vs 2022 (€ 3,285) Favourable step	€ 69,095 Cash 2024: € 69,095 ▲ 87% vs 2023 (€ 36,927) Favourable step	€ 44,927 Cash 2025: € 44,927 ▼ 35% vs 2024 (€ 69,095) Unfavourable step	▼ 35%
Retained profit	€ -177,316 Retained profit 2022: € -177,316 First fiscal year in the series	€ -85,945 Retained profit 2023: € -85,945 ▲ € 91,371 vs 2022 (€ -177,316) Favourable step	€ -22,194 Retained profit 2024: € -22,194 ▲ € 63,752 vs 2023 (€ -85,945) Favourable step	€ -18,112 Retained profit 2025: € -18,112 ▲ € 4,082 vs 2024 (€ -22,194) Favourable step	▲ € 4,082
Balance sheet total	€ 3,297 Balance sheet total 2022: € 3,297 First fiscal year in the series	€ 68,183 Balance sheet total 2023: € 68,183 ▲ € 64,886 vs 2022 (€ 3,297) Unchanged	€ 70,897 Balance sheet total 2024: € 70,897 ▲ 4% vs 2023 (€ 68,183) Unchanged	€ 49,225 Balance sheet total 2025: € 49,225 ▼ 31% vs 2024 (€ 70,897) Unchanged	▼ 31%

Key figures of Newton Biocapital II Partners, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Newton Biocapital II Partners?

What happened at Newton Biocapital II Partners in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 2, 2026 New annual accounts for financial year 2025: profit of € 4,082 (▼ 94% vs 2024). Source: NBB ↗
2024 ROAD MEDICAL GODOKAISHA S. Etr. became a director. NBB
2022 BIOSS S. Etr. became a director. NBB
May 5, 2021 New establishment in Sint-Pieters-Woluwe. KBO
2021 DANNY GONNISSEN SRL became a director. NBB
2021 HEYNEN CONSULTING AG S. Etr. became a director. NBB
2021 A Q INVEST SRL became a director. NBB
May 4, 2021 Start of the company according to the CBE. KBO

In short

From € 175,540 loss in 2022 to € 4,082 profit in 2025.

Paid € 8,717 in corporate taxes since 2022.

Best year ever: 2023, with € 91,371 profit.

Original PDFs at the National Bank ↗

A new publication or filing at Newton Biocapital II Partners? We notify you, reason included.

Follow Newton Biocapital II Partners

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

A Q INVEST 16.9%

DANNY GONNISSEN 16.9%

The stake of A Q INVEST, DANNY GONNISSEN comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

Newton Biocapital II Partners

Behind Newton Biocapital II Partners are DANNY GONNISSEN SRL, HEYNEN CONSULTING AG S. Etr., ROAD MEDICAL GODOKAISHA S. Etr., A Q INVEST SRL and BIOSS S. Etr.. The shares are held by A Q INVEST (16.9%) and DANNY GONNISSEN (16.9%).

See the full network in the app